Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shigeki Okamoto

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
American Journal of Ophthalmology|January 1, 2004
Evaluation of the tear film stability after laser in situ keratomileusis using the tear film stability analysis systemTomoko Goto, Xiaodong Zheng, Stephen D Klyce, et al.
Ophthalmology|December 27, 2016
Steroid-Sparing Effect of 0.1% Tacrolimus Eye Drop for Treatment of Shield Ulcer and Corneal Epitheliopathy in Refractory Allergic Ocular DiseasesDai Miyazaki, Atsuki Fukushima, Yuichi Ohashi, et al.
American Journal of Ophthalmology|December 26, 2006
Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha(1)-adrenoceptor antagonistTetsuro Oshika, Yuichi Ohashi, Mikio Inamura, et al.
Current Eye Research|April 6, 2019
Topical Tacrolimus for Chronic Allergic Conjunctival Disease with and without Atopic DermatitisJun Shoji, Yuichi Ohashi, Atsuki Fukushima, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|May 16, 2009
A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitisNobuyuki Ebihara, Yuichi Ohashi, Eiichi Uchio, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|March 24, 2010
A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitisYuichi Ohashi, Nobuyuki Ebihara, Hiroshi Fujishima, et al.
Allergology International : Official Journal of the Japanese Society of Allergology|February 25, 2012
Blood level of tacrolimus in patients with severe allergic conjunctivitis treated by 0.1% tacrolimus ophthalmic suspensionNobuyuki Ebihara, Yuichi Ohashi, Hiroshi Fujishima, et al.
The British Journal of Ophthalmology|April 4, 2014
Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvementAtsuki Fukushima, Yuichi Ohashi, Nobuyuki Ebihara, et al.
Nippon Ganka Gakkai Zasshi|July 9, 2011
[A prospective, observational, all-prescribed-patients study of cyclosporine 0.1% ophthalmic solution in the treatment of vernal keratoconjunctivitis]Etsuko Takamura, Eiichi Uchio, Nobuyuki Ebihara, et al.
Japanese Journal of Ophthalmology|October 7, 2020
Reduced steroid-induced intraocular pressure elevation in tacrolimus-treated refractory allergic ocular diseasesDai Miyazaki, Daisuke Shimizu, Atsuki Fukushima, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
American Journal of Ophthalmology|January 1, 2004
Evaluation of the tear film stability after laser in situ keratomileusis using the tear film stability analysis systemTomoko Goto, Xiaodong Zheng, Stephen D Klyce, et al.
Ophthalmology|December 27, 2016
Steroid-Sparing Effect of 0.1% Tacrolimus Eye Drop for Treatment of Shield Ulcer and Corneal Epitheliopathy in Refractory Allergic Ocular DiseasesDai Miyazaki, Atsuki Fukushima, Yuichi Ohashi, et al.
American Journal of Ophthalmology|December 26, 2006
Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha(1)-adrenoceptor antagonistTetsuro Oshika, Yuichi Ohashi, Mikio Inamura, et al.
Current Eye Research|April 6, 2019
Topical Tacrolimus for Chronic Allergic Conjunctival Disease with and without Atopic DermatitisJun Shoji, Yuichi Ohashi, Atsuki Fukushima, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|May 16, 2009
A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitisNobuyuki Ebihara, Yuichi Ohashi, Eiichi Uchio, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|March 24, 2010
A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitisYuichi Ohashi, Nobuyuki Ebihara, Hiroshi Fujishima, et al.
Allergology International : Official Journal of the Japanese Society of Allergology|February 25, 2012
Blood level of tacrolimus in patients with severe allergic conjunctivitis treated by 0.1% tacrolimus ophthalmic suspensionNobuyuki Ebihara, Yuichi Ohashi, Hiroshi Fujishima, et al.
The British Journal of Ophthalmology|April 4, 2014
Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvementAtsuki Fukushima, Yuichi Ohashi, Nobuyuki Ebihara, et al.
Nippon Ganka Gakkai Zasshi|July 9, 2011
[A prospective, observational, all-prescribed-patients study of cyclosporine 0.1% ophthalmic solution in the treatment of vernal keratoconjunctivitis]Etsuko Takamura, Eiichi Uchio, Nobuyuki Ebihara, et al.
Japanese Journal of Ophthalmology|October 7, 2020
Reduced steroid-induced intraocular pressure elevation in tacrolimus-treated refractory allergic ocular diseasesDai Miyazaki, Daisuke Shimizu, Atsuki Fukushima, et al.
Pageof 3